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Abstract
Background: Several guidelines to reduce cardiovascular risk in diabetes patients exist in North America, Europe, and
Australia. Their ability to achieve this goal efficiently is unclear.
Methods and Findings: Decision analysis was used to compare the efficiency and effectiveness of international
contemporary guidelines for the management of hypertension and hyperlipidemia for patients aged 40–80 with type 2
diabetes. Measures of comparative effectiveness included the expected probability of a coronary or stroke event,
incremental medication costs per event, and number-needed-to-treat (NNT) to prevent an event. All guidelines are equally
effective, but they differ significantly in their medication costs. The range of NNT to prevent an event was small across
guidelines (6.5–7.6 for males and 6.5–7.5 for females); a larger range of differences were observed for expected cost per
event avoided (ranges, $117,269–$157,186 for males and $115,999–$163,775 for females). Australian and U.S. guidelines
result in the highest and lowest expected costs, respectively.
Conclusions: International guidelines based on the same evidence and seeking the same goal are similar in their
effectiveness; however, there are large differences in expected medication costs.
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Introduction
Clinical practice guidelines are viewed as useful tools for making
care more consistent and efficient and for closing the gap between
what clinicians do and what scientific evidence supports. Interest
in clinical guidelines is international and has its origin in issues
faced by most healthcare systems: rising healthcare costs; variation
in service delivery with the presumption that at least some of this
variation results in inappropriate care; and a mechanism for
providing patients the best care possible.
An Institute of Medicine report on clinical guidelines recom-
mended that information on cost implications be incorporated into
guidelines; however, the report acknowledged that major methodo-
logical and practical challenges exist to implement this recommen-
dation. [1] Over the last two decades the number of guidelines has
grown internationally, and within the United States (US), but costs
have generally not been considered in the US. [2] Thus, the influence
of incremental guideline changes on cost is unclear. The debate on
healthcare reform and methods for ‘‘bending the cost curve’’
motivate the importance of understanding efficiency of guidelines.
Although the burden of cardiovascular risk among diabetes
patients is comparable across developed countries, there are often
differences in treatment guidelines. [3] For instance, there are
different thresholds for treatment decisions and medication
management that do not directly reflect the available evidence,
such as LDL-cholesterol levels for starting medication therapy. [4]
The lack of transparency about guideline formulation has led to
criticisms, and the perception that conflicts of interest may have
influenced their recommendations. [2,5,6] Given the variation in
the development and implementation of treatment guidelines
internationally, it is necessary to classify the most efficient
strategies. This is an increasingly important issue, given the
simultaneous increase in healthcare costs and diabetes incidence.
[7,8]
We conducted a comparative effectiveness analysis of interna-
tional contemporary guidelines for the management of hyperten-
sion and hyperlipidemia for patients with type 2 diabetes. In order
to demonstrate the impact of changes in consensus recommenda-
tions, we include historical antecedent guidelines from the US. To
compare these guidelines, we use a Markov model for type 2
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diabetes to estimate measures related to primary prevention
including the probability of a coronary heart disease (CHD) or
stroke event, number-needed-to-treat (NNT), and expected
medication cost per event avoided.
Methods
Markov Model
Our Markov model is a natural history model for type 2
diabetes patients, ages 40 to 80 years, considering three modifiable
risk factors: blood glucose, hypertension, and hyperlipidemia.
Figure 1 illustrates the probabilistic transitions in our model that
estimates probability of an event for a given patient and treatment
guideline. Appendix S1 presents additional details of the model
and its assumptions. For the management of hyperlipidemia, we
consider treatment with statins followed by fibrates; for hyperten-
sion management we consider treatment in the order of thiazides,
angiotensin receptor blockers (ARBs)/angiotensin converting
enzyme (ACE) inhibitors, beta-blockers, and calcium channel
blockers (CCBs).
Key assumptions
We assume that treatment decisions regarding the initiation of
new drug therapies are revisited annually. Hyperlipidemia
medications result in a proportional decrease in total cholesterol
and increase in HDL levels; hypertension medications result in a
proportional decrease in systolic (SBP) and diastolic blood pressure
(DBP). We assume additive treatment effects for medications that
influence the same risk factor. We do not consider revasculariza-
tion procedures in the absence of a cardiovascular event. We also
assume that the rate of adverse effects will be similar across all
guidelines. We assume that patients will have perfect adherence to
medications. Finally, this paper evaluates the impact of these
guidelines in a US population and uses US prices for the
medications. If the populations and prices are used for each of the
countries and their populations, we would expect the results to be
different.
Key variables
Additional Markov model variables include patient demograph-
ics (sex, age, and time of diagnosis of diabetes) and metabolic
characteristics (blood pressure, lipid, and HbA1c levels). We refer
to the combination of lipids and blood pressure states with the
patient’s mean HbA1c as the patient’s metabolic state. We combine
this information with the patient’s demographic characteristics and
medication history to define the patient’s CHD and stroke risk
profile. We refer to this combination as the patient’s health state.
Data and Model Inputs. We use the Mayo Clinic Diabetes
Electronic Management System (DEMS) Data Set [9] to estimate
model parameters including the transition probabilities among the
metabolic states. DEMS is a diabetes data management system
based on longitudinal medical records for diabetes patients at
Mayo Clinic. Our cohort includes 663 patients in DEMS between
1997 and 2006 with type 2 diabetes, aged 40 to 80 during the
observation period. These patients had approximately 15,000
measurements of cholesterol, blood pressure and HbA1c. These
data are also used to estimate mean treatment effects for
hyperlipidemia and hypertension medications.
Of the metabolic factors, triglycerides and HbA1c are modeled
as a function of age. Due to the uncertain nature of cholesterol
levels of a patient over time, we treat the progression of total
cholesterol and HDL-cholesterol levels as a Markov process, each
with a finite set of states (Figure 2), and then estimate LDL levels
using Friedewald’s equation. [10] SBP is also treated as a Markov
process. A major advantage of our model is that it is developed
based on 10-year observation period for each individual (except
those that died during the observation period (1.7%)) and it
simulates change in risk factors over time.
Cardiovascular and stroke event rates
Probabilities for initial CHD and stroke events are calculated
from the United Kingdom Prospective Diabetes Study (UKPDS)
risk equations. [11,12,13] These probabilities depend on health
states and age, and reflect the changes in the patient’s health and
medical treatment status. We focus on primary prevention, and
Figure 1. Illustration of the Markov model for treatment of type 2 diabetes. Transitions between states occur annually. Patients transition
among health states defining the risk of CHD or stroke events, and treated health states based on treatment guidelines.
doi:10.1371/journal.pone.0016170.g001
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therefore we do not examine the details of a patient’s course after
the first cardiovascular or stroke event, or death from other causes.
Probability of death from other causes was estimated using data
from the National Center for Health Statistics mortality rate
tables. [14,15]
Treatment Efficacy
We use patient-level data from our cohort to estimate the effect
of each of the medications on the metabolic factors. Appendix S2
presents the details of these calculations. Table 1 shows the
estimated treatment effects of medications that were incorporated
into the model. We assumed no interaction in the effects of
medications for hypertension and hyperlipidemia.
Costs
We conducted the analysis from the perspective of a third-party
payer. We consider incremental medication costs that are directly
associated with the management of hypertension and hyperlipidemia.
Drug costs were obtained from the 2009 Red Book average wholesale
prices. [16] For our base-case analysis, we estimated the annual
medication costs using the lowest Red Book prices for simvastatin,
gemfibrozil, lisinopril, metoprolol, hydrocholorothiazide, and amlo-
dipine (Table 2). We also conducted sensitivity analyses using the
highest listed Red Book prices for each medication class. Costs
associated with medications for glycemic control were not considered.
Guidelines
We compare guidelines using our Markov model to represent
progress. The patient’s risk factors evolve over time from a starting
age of 40 until the time of the first event. Medication is initiated at
annual intervals whenever the patient meets the guideline criteria.
In contrast to other studies of cardiovascular risk management in
patients with diabetes [17] our approach assumes the patient is
treated incrementally, over time, as the risk evolves with age.
We considered the Adult Treatment Panel (ATP) II [18] and III
[19], the Sixth [20] and Seventh [21] reports of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment,
of High Blood Pressure (JNC 6, JNC 7), Canadian [22,23],
European societies [24], British [25], and Australian [26,27]
guidelines for treatment of hyperlipidemia and hypertension. The
guidelines are summarized in Table 3. US I represents the
combination of the ATP II and JNC 6 guidelines, and US II
represents the combination of ATP III and JNC 7 guidelines. We
also evaluate three reference guidelines related to US guidelines: 1)
initiating statins and ACE-inhibitors at the time of diagnosis with
no further intensification or changes in treatment for the
management of hypertension and lipids (Initiate at Diagnosis), 2)
JNC 7 and the standard ATP III guidelines without considering
diabetes as a risk equivalent (US III); and 3) initiating statins and
ACE-inhibitors at the time of diagnosis and then following ATP
III and JNC 7 (US IV). Table 3 presents a summary of the
guideline combinations.
In addition to the above guidelines we also evaluated the impact
of intensive blood pressure control as recently reported in the
ACCORD study. [28] In this case lipids were managed using the
standard ATP III guideline and hypertension was managed to a
target SBP of 120 mm/Hg. We did not consider the case of
combination lipid-lowering therapy as considered in ACCORD
[29]; patients received combination treatment as recommended by
the ATP III guidelines.
Outcome Measures
We evaluated the performance of the guidelines based on
implications for patient outcomes, clinical policy, and health
policy. Patient outcomes are measured by the probability of CHD
or stroke event. Clinical policy measures include the NNT for a
lifetime (represented here by the span of time from age 40 until
death or age 80), and the number of events avoided per 1,000
patients treated. Health policy implications are measured by
expected medication costs per event avoided. We use a 3% annual
discount rate for costs. [30]
Role of the funding source
The Agency for Healthcare Research and Quality (AHRQ) and
the National Science Foundation (NSF) had no role in the study
design, conduct, analysis, or manuscript preparation for this study.
Figure 2. Cut-points used to define the health states for the
Model (TC=Total Cholesterol; HDL=High Density Lipoprotein
Cholesterol; SBP = Systolic Blood Pressure; DBP=Diastolic
Blood Pressure).
doi:10.1371/journal.pone.0016170.g002
Table 1. Effects of medication initiation on metabolic factors for the most commonly used medications.
% Change
Treatment Total Cholesterol HDL Systolic Blood Pressure Diastolic Blood Pressure
Statins 214 7.3
Fibrates 23.9 4.7
ACE-Inhibitors/Angiotensin
Receptor Blockers
23.7 25.5
Thiazides 25.0 23.7
Beta-Blockers 24.6 24.2
Calcium Channel Blockers 22.5 24.8
doi:10.1371/journal.pone.0016170.t001
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Results
Base Case
The time horizon spanned ages 40 to 80 years. We evaluated
the guidelines for Caucasian, non-smoking patients of both sexes,
diagnosed with type 2 diabetes at age 40 and with no prior history
of CHD, stroke or cardiac disorders. The proportion of patients in
each health state at age 40 was based on our study cohort.
Figures 3 and 4 present the probability of an event, and the
expected medication cost for each of the guideline combinations
using a discount factor of 3%.
Assuming no treatment, the probability of an event between
ages 40 to 80 was 68.5 percent for male patients, and 54.5 percent
for female patients. Using US III decreased the probability of an
event to 54.8 percent for males and 41.2 percent for females. For
both sexes, there were some differences in the probability of an
event across the international guidelines; however, these differ-
ences were small. The maximum difference in the probability of
having an event across guidelines was 2.1 percent for males and
2.2 percent for females. The Australian guideline combination had
the lowest probability of incurring an event (52.7% for males and
39.0% for females). The guideline with the highest probability of
an event was US III (54.8% for males and 41.2% for females).
From a clinical policy perspective, it is important to consider the
role of both hypertension and hyperlipidemia guidelines since their
collective goal is primary prevention. We observed small variation
in the NNT across guidelines (Table 4). Australian, British,
European and Canadian guidelines resulted in the lowest NNT for
males and females; the highest NNT was for the risk blind
initiation at diagnosis of statins and ACE inhibitors with no further
management of hypertension or lipids (NNT=14.4 for males and
11.7 for females). Among the US guidelines, the NNT was highest
for the US III guidelines (NNT=7.6 for males and 7.5 for
females). The changes from US I to US II for diabetes required an
increased intensification of lipid and blood pressure control. These
incremental changes in guidelines did not have a significant impact
in changing the absolute risk for primary prevention.
From a health policy perspective, there were differences in the
expected medication costs across the guidelines and between sexes.
With the base-case (lower) costs of medication, for males, the
expected medication costs varied between $15,509 (US III) and
$24,186 (Australian), and for females between $15,433 (US III) to
$25,267 (Australian). For the highest estimate of medication costs
(specifically, branded medications), expected medication costs varied
between $57,085 (US III) and $87,961 (Australian) for males, and
between $57,792 (US III) and $91,691 (Australian) for females.
We estimated the policy implications for each of the guidelines.
The US III guideline had the lowest expected medication costs per
event avoided per 1,000 diabetes patients ($117,269 for males;
$115,999 for females). The Australian guideline combination was
the most expensive. The incremental expected medication costs
per event avoided (per 1,000 diabetes patients) when going from
US I to US II was $335,310 for males and $384,175 for females.
Evaluation of guidelines with intensive blood-pressure manage-
ment, as reported by ACCORD, showed that the impact of
intensive treatment was small compared to US II guidelines
Table 2. Annual medication costs.
Drug Class Base-case Upper Bound
Statins $ 212 $ 1,258
Fibrates $ 652 $ 1,452
Angiotensin Converting Enzyme (ACE) Inhibitors/Angiotensin II Receptor Blockers $ 48 $ 868
Thiazides $ 48 $ 946
Beta Blockers $ 48 $ 145
Calcium Channel Blockers $ 866 $ 1,031
doi:10.1371/journal.pone.0016170.t002
Table 3. Description of Guidelines (recommendations below are thresholds for treatment initiation).
Guideline Hyperlipidemia Hypertension
Initiate at Diagnosis Initiate statins when diagnosed with diabetes with no further
measurement or intensification
Initiate ACE-Inhibitors at diagnosis with no further
measurement or initiation
United States I ATP II: LDL$130 mg/dL JNC 7: SBP.130 mm Hg or DBP.85 mm Hg
United States II ATP III: LDL$100 mg/dL JNC 7: SBP.130 mm Hg or DBP.80 mm Hg
United States III ATP III: Calculate risk based on individual risk factors and treat
to goal based on risk-factors (High risk: LDL$100 mg/dL;
moderate risk: LDL$130 mg/dL; low risk: LDL$190 mg/dL)
JNC 7: SBP.140 mm Hg or DBP.90 mm Hg
United States IV Initiate statins when diagnosed with diabetes and intensify
according to ATP III guidelines
Initiate ACE-Inhibitors when diagnosed with diabetes
and intensify according to JNC 7 guidelines
Canada LDL$2.5 mmol/L or LR$4 SBP.130 mm Hg or DBP.80 mm Hg
European Societies LDL$2.5 mmol/L or TC$4.5 mmol/L SBP.130 mm Hg or DBP.80 mm Hg
Joint British Societies LDL$2.0 mmol/L or TC$4 mmol/L SBP.130 mm Hg or DBP.80 mm Hg
Australia LDL$2.5 mmol/L or TC$ mmol/L or HDL,1 mmol/L SBP.130 mm Hg or DBP.80 mm Hg
doi:10.1371/journal.pone.0016170.t003
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Figure 3. Efficient Frontier for Treatment Guidelines for Males.
doi:10.1371/journal.pone.0016170.g003
Figure 4. Treatment Guidelines for Females.
doi:10.1371/journal.pone.0016170.g004
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(NNT=222 for males and NNT=258 for females). In addition,
the incremental cost increase per event avoided per 1,000 diabetes
patients was $1.4 million for males and $1.7 million for females.
Discussion
Key findings
Our results suggest that the various treatment guidelines for
hyperlipidemia and hypertension for diabetes patients have
become increasingly similar in their effectiveness in recent years.
However, there are differences in lifetime medication costs for the
management of hyperlipidemia and hypertension.
A surprising finding was that the US guidelines are generally
more efficient compared to other published guidelines. This is
largely due to the lower lipid targets being pursued by the other
countries/regions. It is important to note that there is little
variation among hypertension guidelines, and thus the differences
in results are largely driven by differences in lipid management.
Sensitivity analysis using a range of US costs for medications did
not change the relative efficiency. Australian guidelines have the
highest and US guidelines the lowest expected medication costs per
event avoided. Changes in treatment guidelines from ATP II to ATP
III, and from JNC 6 to JNC 7, simultaneously increased the expected
costs per event avoided. More importantly, the benefits of these
changes were minimal as evidenced by the large NNT. Figures 3 and
4 show that the relative order of efficiency of contemporary
guidelines is generally the same for males and females.
We found that the ATP III guidelines that consider diabetes as a
cardiovascular risk equivalent decreased the probability of having
an event by 1.8 percent for males and by 1.9 percent for females
compared to US III. Among US guidelines, US IV has the lowest
probability of an event for both males and females; however, this
strategy also has the highest cost. Simulation of intensive treatment
as suggested by ACCORD showed relatively small benefit for
significantly higher costs as suggested by the results of the trial.
[28] Sensitivity analysis with higher medication costs did not
change these results. However, these analyses point out the large
differences in costs that can be incurred based on the choice of
medications. The routine use of branded drugs can increase the
lifetime costs of medications by almost four fold for both males
($79,915 compared to $20,931) and females ($83,558 compared to
$21,970).
Implications
The results of our analyses suggest that there are significant
differences in patient outcomes, clinical policy, and health policy
measures. According to our model if one were to treat 1 million
males with newly diagnosed type 2 diabetes according to the most
costly (Australian) and current US guidelines (US II), there would
be significant differences in societal costs with minimal differences
in outcomes. The Australian guidelines would be expected to incur
an additional expected medication cost of $3.3 trillion dollars and
lead to 2,518 fewer people experiencing a cardiovascular event.
A previous evaluation comparing guidelines for the manage-
ment of hyperlipidemia found that the New Zealand guideline was
the most efficient while the ATP III guidelines were least efficient.
[31] The ATP III guidelines would have treated twice as many
individuals as the New Zealand guidelines; however, it would have
prevented a similar number of deaths. Interestingly, in our
analysis, all international guidelines would lead to fewer events,
but they would also be more costly than the US guidelines. These
differences may be due to the recent changes in international
guidelines where diabetes is considered a cardiovascular risk
equivalent. In our analysis, we did not separate out the New
Zealand guidelines since they are the same as the Australian
guidelines for diabetes patients. Recent results by Timbie et al.
suggest that, even among diabetes patients, a risk-targeted
approach may lead to greater benefits and fewer harms. [17] It
is important for policy makers to consider these tradeoffs that may
be incorporated implicitly within guidelines as health care
spending becomes an increasingly finite resource that needs to
be managed more efficiently.
Limitations and strengths
There are several limitations associated with our analyses. Our
Markov model is based on point estimates of transition probabilities
Table 4. Impact of Guidelines.
Guidelines Guideline Impact Guideline Impact
Males Females
Number Needed
To Treat
Number of
Events Avoided
per 1,000
Treated
Medication
Costs per
Event
Avoided
Number
Needed To
Treat
Number of
Events Avoided
per 1,000
Treated
Medication Costs per
Event Avoided
United States I 7.0 142.6 $129,428 6.9 145.6 $134,655
United States II 6.7 150.4 $139,204 6.6 151.8 $144,773
United States III 7.6 132.3 $117,269 7.5 133.0 $115,999
United States IV 6.6 151.4 $141,185 6.6 152.5 $147,011
Canada 6.6 152.8 $147,705 6.5 153.6 $153,952
European Societies 6.5 153.3 $152,385 6.5 153.9 $158,784
Joint Bristish Societies 6.5 153.8 $156,817 6.5 154.1 $163,488
Australian 6.5 153.9 $157,186 6.5 154.3 $163,775
Statin + ACE Inhibitor
with no guideline
14.4 81.0 $63,708 11.7 70.7 $75,886
*United States III - Assumes diabetes as a cardiovascular risk equivalent.
**United States IV - Immediate initiation of statins and ACE Inhibitors after diagnosis of diabetes.
doi:10.1371/journal.pone.0016170.t004
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among metabolic states, cost parameters and literature driven
cardiovascular event probabilities, and each estimate is subject to
statistical variance. Another potential source of error is model
uncertainty. An example of model uncertainty is our assumption
that costs for non-pharmaceutical medical care for the management
of cardiovascular disease in different countries for type 2 diabetes
patients are the same. A further limitation is that we did not consider
medication adverse effects, non-adherence and discontinuation. We
partially addressed this through estimating the medication effec-
tiveness from observational data. We assume that all other medical
costs for patients will be equal across the guidelines and thus, focus
our comparison on medication costs.
We estimate risk reduction of initiating medications based on
the UKPDS risk equation by incorporating the changes in
laboratory values after initiating medication. However, the Heart
Protection Study suggests that statins used at fixed doses without
monitoring for achievement of a lipid goal and without dose
titration could reduce CV risk by 25% regardless of the extent to
which that statin dose reduced lipid levels. [32] This could
influence the relative efficiency of guidelines.
Our model has several advantages. We use longitudinal patient-
level observational data to calibrate a natural history model of
hyperlipidemia and hypertension progression over time. In contrast
to previous studies we evaluate guidelines based on their application
to treatment over the course of a patient’s lifetime as their CHD and
stroke risk evolves. [17] Although, our data is restricted to a single
health care institution, it provides a data set which is rich enough in
clinical information that is necessary for our model. Finally, we use
estimates of the effectiveness of medications in the real world as
opposed to previously publishedmodels which use data from clinical
trials that may overstate effectiveness due the selection bias and the
rigor associated with clinical trials. [33],[34] On the other hand, we
did not include unintended consequences or side effects that could
have decreased the efficacy of the intervention in reducing CHD or
stroke events (e.g., intensive blood pressure control leading to
hypotension and stroke).
Conclusion
Hyperlipidemia and hypertension guidelines have a large
societal impact as they treat a large portion of the population
and result in high costs. Used in combination, hyperlipidemia and
hypertension medications can significantly lower the probability of
a cardiovascular event or stroke in the diabetes population. There
are significant differences in medication cost for patients treated
under different international guidelines; however, the reduction in
probability of events is similar across guidelines. The recent results
from the ACCORD and INVEST trials raise questions about the
impact of intensive hypertension management. [35],[28] Policy-
makers implementing healthcare reform must evaluate the current
guidelines and the associated tradeoffs in benefits, risks, and costs.
A more risk targeted approach for the management of
cardiovascular risk for diabetes patients has the potential to have
large benefits while reducing costs.
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